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Abstracts / Osteoarthritis and Cartilage 23 (2015) A82eA416 A297Methods: Actﬂ/ﬂ mice were crossed with a ubiquitously expressed
inducible Cre recombinase line (UbiCreERT2). Male and female mice
homozygous for the ﬂoxed allele and positive for Cre recombinase were
treated with tamoxifen at 8 weeks of age to induce deletion of the gene
in all tissues. Actﬂ/ﬂmice (without Cre) were used as negative controls.
OA was induced by destabilization of the medial meniscus. 8 weeks
following surgery joints were taken for microCT analysis to measure
epiphyseal volume according to our previously published method (Das
Neves Borges et al, 2014) and serial histology for assessment of cartilage
degradation.
Results: No overt deleterious effect of global post natal activin bA
deletion was observed. Knockout mice were noted to have delayed hair
regrowth following shaving (prior to surgery). Cartilage degradation
scores showed a trend towards being lower in knockout compared with
wild type animals although this did not reach statistical signiﬁcance.
Epiphyseal volume, a validated measure of osteophyte size, was sig-
niﬁcantly reduced in female, but not male, knockout mice. By histology,
osteophytes were present in female knockout mice but were very small
compared with male knockout animals or the wild type controls.
Conclusions: We have uncovered a novel role for activin bA in the
development of osteophytes following joint destabilization that is
restricted to female mice. Although there was a trend towards reduced
cartilage degradation scores in knockout animals, these did not reach
signiﬁcance.
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IGF-II INHIBITS PROMOTES CARTILAGE INTEGRITY IN
EXPERIMENTAL OSTEOARTHRITIS AND IL-1b-INDUCED CATABOLIC
ACTIVITY IN CHONDROCYTES
L. Zeng y, T. Uchimura y, A. Foote y, E. Matzkin z, E. Smith z. y Tufts Univ.
Sch. of Med., Boston, MA, USA; z Tufts Med. Ctr., Boston, MA, USA
Purpose: The goal of this study was to investigate the effect of IGF-II on
chondrocyte catabolic gene expression under pro-inﬂammatory cyto-
kine IL-1b treatment and on cartilage matrix levels in OA.
Methods: IN VITRO: Normal human articular chondrocytes (Lonza)
were cultured in the presence or absence of IL-1b or lentiviral hIGF-II or
GFP, and subjected to RT-PCR and Western blot analysis. IN VIVO: CD1
mice were subjected to DMM (destabilization of medial meniscus)
surgery. Lenti-IGF-II or GFP were intraarticularly injected at 1 and 2
weeks post DMM or sham surgery (6 mice/treatment). Safranin O
staining and Immunohistochemistry (IHC) were performed on sec-
tioned knees and scored by Image J and the OARSI scoring system. EX
VIVO: human OA cartilage slices were cultured in the presence of IGF-II
(10ng/ml) for 3 weeks and matrix level was analyzed by IHC and
safranin/O staining. Data are reported asmean ± standard deviation. For
parametric data, one-way analysis of variance followed by post-hoc
Tukey test was used. For nonparametric data (OARSI scores), we used
Kruskal-Wallis test followed by Mann-Whitney U test with Bonferroni
correction. P-values of <0.05 were considered signiﬁcant.
Results: To ascertain IGF expression in OA cartilage, we performed RT-
qPCR analysis using cartilage specimens obtained from the tibial pla-
teaus of a cadaveric donor and three OA patients undergone total knee
replacement surgery. We found that the expression of IGF-II, but not
IGF-I, was reduced in OA cartilage, while IL-1b and MMP13 were
increased in OA (Data not shown). We then tested whether IGF-II could
antagonize IL-1b activity in primary human articular chondrocytes, and
found that co-treatment of IL-1b with IGF-II restored Col-II and Col-IX
expression and inhibited Col-I, MMPs and iNOS induction (Fig. 1A).
Furthermore, treatment of IL-1b with IGF-II signiﬁcantly inhibited NF-
kB nuclear localization and IkBa degradation (Fig. 1B), as well as NFATc2
nuclear localization (data not shown). As phospholipase C (PLC) has
been reported to act downstream of IGF-I and IGF-II in chondrocytes,
we used a PLC inhibitor U73122, and found that IGF-II no longer pre-
vented IL-1b-induced MMP13 expression upon U73122 treatment. In
contrast, an inactive analog of PLC inhibitor, U73343, could not prevent
IGF-II from inhibiting MMP13 expression (Fig. 1C), suggesting that PLC
mediates IGF-II activity with this respect.
To determine the effect of IGF-II on articular cartilage in OA in vivo, we
utilized the DMMmousemodel, wherewe found IGF-II expression to be
decreased in the DMM knee joint as compared to the sham (Fig. 2A). We
then ectopically expressed IGF-II in mouse OA joints through intra-
articular injection of lentiviruses encoding IGF-II or GFP (control) at 1
and 2 weeks after the surgery. The efﬁciency of viral transduction was
assessed by IHC (data not shown), and joint integrity was analyzed bySafranin O staining. No signiﬁcant differences were observed between
lentiviral-IGF-II or GFP treated sham knees. However, lentiviral-IGF-II
injected DMM knee joints retained more Safranin O staining and had
smaller osteophyte formation compared to DMM joints injected with
the GFP virus (Fig. 2B and 2C). Furthermore, ectopic IGF-II expression
signiﬁcantly reduced MMP13 and NFkB (p65) expression in the DMM
knee joints (Fig. 2C and data not shown). Consistent with the mouse
data, we also found that IGF-II led to stronger safranin/O staining and
higher levels of Col-II expression, as well as reduced levels of MMP13
expression in human OA cartilage explants (Fig. 2D). Although it is
unclear whether IGF-I has a similar activity as IGF-II in OA, explant
cultures using IGF-II deﬁcient mouse metatarsal bones indicated that
IGF-II, but not IGF-I, could rescue IL-1b-mediated cartilage matrix
damage, suggesting of a functional difference between the two growth
factors (data not shown).
Conclusions: 1. IGF-II inhibits IL-1b-induced matrix gene reduction and
NF-kB and NFAT activation in human articular chondrocytes in vitro,
and its activity is mediated by PLC.
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induced OA in mice and in human OA cartilage ex vivo cultures.
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CHANGES IN PATELLOFEMORAL BONE MARROW LESIONS AND KNEE
PAIN: NATURAL HISTORY AND THE ASSOCIATIONS WITH STRUCTURE
Z. Zhu y, C. Ding y, X. Jin y, B. Antony y, W. Han y, L. Laslett y, F. Cicuttini z,
G. Jones y. yMenzies Inst. for Med. Res., Hobart, Australia; zDept. of
Epidemiology and Preventive Med., Monash Univ., Melbourne,
Melbourne, Australia
Purpose: Bone marrow lesions (BMls) are recognized as an important
subchondral feature in knee OA and play a vital role in the diease
progression. The patellofemoral joint (PFJ) is a common site of pain and
contributes to functional limitations among OA patients. However,
there are very few clinical or epidemiological studies that reveal the
association between PFJ BMLs and clinical symptoms as well as cartilage
structural morphologies. Meanwhile, the natural history of PFJ BMLs
has not yet been described. The aims of this study were, therefore, to
describe the natural history of MRI-detected BMLs in PFJ over 2.6 years
and evaluate the association between increases in PFJ BMLs, knee pain
and knee cartilage morphology in older adults.
Methods: 406 males and females were randomly selected from local
community (mean age 63 years, range 51 to 79) and followed up for 2.6
years. PFJ BMLs were determined on T2-weighted fat saturated mag-
netic resonance imaging (MRI) using Whole-Organ MRI Score system
(WORMS). Knee cartilage volume and cartilage defects scores (0-4)
were determined on T1-weighted fat suppression MRI using WORMS.
Knee pain was accessed byWestern Ontario and McMaster Universities
Osteoarthritis (WOMAC) scores. Student's t-tests and Pearson's c2 tests
were used to compare the differences between subjects with and
without an increase in PFJ BMLs. Crude and adjusted linear regression
was used to determine whether PFJ BML changes over 2.5 years were
associated with changes in knee pain in the different sub-scales over 5
years, before and after adjustment for potential confounders. Binary
logistic regression was used to examine the associations between
increases in PFJ BMLs as an outcome, and baseline cartilage volumes as
well as baseline cartilage defect scores as predictors, both before and
after adjustment for potential confounders.
Results: At baseline, 27% (n¼109) had PFJ BMLs, 24% of these showed
progression (change in score of 1) at follow-up, 44% persisted and 21%
completely resolved. Of those 73% (n¼297) who did not have PFJ BMLs
at baseline, 19.7% of them developed new PFJ BMLs over 2.6 years. In
multivariable analysis, change in PFJ BMLs was positively associated
with increases in total knee pain (b: 0.81, 95% CI: 0.15, 1.48) and knee
pain when going up/down stairs (b: 0.29, 95% CI: 0.08, 0.50) over 5years. While baseline patellar cartilage volume predicted a decrease in
PFJ BMLs (OR: 0.62, 95% CI: 0.43, 0.90), baseline patellar cartilage
defects were associated with an increase in PFJ BMLs (OR: 1.75, 95% CI:
1.28, 2.40) over 2.6 years. Tibiofemoral cartilage volume and defects
were not associated with changes in PFJ BMLs.
Conclusions: PFJ BMLs are not static and change is clinically relevant.
An increase in PFJ BMLs can be predicted by reduced patellar cartilage
volume and increased patellar cartilage defects site-speciﬁcally.
